The Journal of Organic Chemistry· 2026Q2
A Unified Phosgene-Free Carbonylation Using CO2 for the Synthesis of Ureas, Carbamates, Carbonates, Amides, and Formamides
- 0citations
- Q2SCImago
- 2026year
Short summary
A new phosgene-free carbonylation platform uses CO2 and phosphorus(V) activators to synthesize ureas, carbamates, carbonates, amides, and formamides under mild, metal-free conditions.
AI-generated from the title and abstract; the full text is not read.
Key points
- Developed a phosgene-free carbonylation platform utilizing CO2 as a C1 synthon.
- Employs phosphorus(V) activators (e.g., POCl3) to generate transient carbonylating species.
- Enables one-pot, three-component synthesis of ureas, carbamates, carbonates, amides, and formamides.
- Operates under mild, metal-free conditions, avoiding toxic preactivated carbonylating reagents.
- Successfully demonstrated by a 25g synthesis of the anticancer drug sorafenib.
AI-generated from the title and abstract; the full text is not read.
Abstract
Abstract Phosgene remains a privileged reagent for carbonylation; however, its extreme toxicity and stringent regulatory controls often restrict its routine and broad application. Herein, we describe a unified CO2-based carbonylation platform for the synthesis of ureas, (thio)carbamates, (thio)carbonates, amides, and formamides under mild, metal-free conditions. The method employs readily available phosphorus(V) activators to generate transient phosphorus-activated carbonyl species that selectively react with amines, alcohols, thiols, hydrides, and organometallic reagents, enabling a one-pot, three-component protocol that telescopes multi-step phosgene-based sequences into a single operation. This approach eliminates the need for phosgene and other preactivated carbonylating reagents. Mechanistic studies are most consistent with the involvement of a transient phosphorus-mediated carbonylating species, conceptually analogous to electrophilic carbonyl transfer in biological systems, although its precise identity remains unresolved. The synthetic utility of the platform is demonstrated by the 25 g synthesis of the anticancer drug sorafenib using POCl3 as the activator. By harnessing CO2 as a C1 synthon, this strategy addresses a long-standing challenge in electrophilic carbonylation and provides an operationally simple and complementary alternative to phosgene-based methods.
The authors' abstract, as published at the source. The Journal of Organic Chemistry, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Process Chemistry and TechnologyChemical Engineering